Brokerages forecast that Lantheus Holdings Inc (NASDAQ:LNTH) will post $83.45 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Lantheus’ earnings, with estimates ranging from $82.80 million to $84.10 million. Lantheus posted sales of $79.94 million during the same quarter last year, which suggests a positive year over year growth rate of 4.4%. The company is expected to report its next earnings report on Thursday, November 1st.
On average, analysts expect that Lantheus will report full-year sales of $339.65 million for the current financial year, with estimates ranging from $339.40 million to $339.90 million. For the next fiscal year, analysts expect that the firm will report sales of $366.10 million per share, with estimates ranging from $363.00 million to $369.20 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Lantheus.
Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Wednesday, August 1st. The medical equipment provider reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.04. The business had revenue of $85.60 million during the quarter, compared to the consensus estimate of $87.90 million. Lantheus had a net margin of 37.53% and a return on equity of 560.19%. The firm’s revenue for the quarter was down 3.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.35 earnings per share.
Several analysts have weighed in on LNTH shares. Credit Suisse Group lowered their price target on shares of Lantheus from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday, August 2nd. Zacks Investment Research raised shares of Lantheus from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 4th. BidaskClub raised shares of Lantheus from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. ValuEngine downgraded shares of Lantheus from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 4th. Finally, Wells Fargo & Co lowered their price objective on shares of Lantheus from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $23.75.
In other news, Director Julie Mchugh sold 4,560 shares of the company’s stock in a transaction dated Monday, June 25th. The shares were sold at an average price of $14.72, for a total transaction of $67,123.20. Following the completion of the transaction, the director now directly owns 14,752 shares of the company’s stock, valued at $217,149.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company’s stock.
Several large investors have recently modified their holdings of the company. Piedmont Investment Advisors LLC purchased a new position in shares of Lantheus during the second quarter valued at about $104,000. Itau Unibanco Holding S.A. purchased a new position in shares of Lantheus during the second quarter valued at about $104,000. NumerixS Investment Technologies Inc increased its position in shares of Lantheus by 1,000.0% during the second quarter. NumerixS Investment Technologies Inc now owns 7,700 shares of the medical equipment provider’s stock valued at $113,000 after buying an additional 7,000 shares during the period. Sun Life Financial INC purchased a new position in shares of Lantheus during the second quarter valued at about $140,000. Finally, SG Americas Securities LLC purchased a new position in shares of Lantheus during the second quarter valued at about $151,000. 92.56% of the stock is owned by hedge funds and other institutional investors.
Lantheus stock opened at $16.30 on Friday. The company has a quick ratio of 3.14, a current ratio of 3.86 and a debt-to-equity ratio of 5.94. The firm has a market capitalization of $593.65 million, a price-to-earnings ratio of 15.85, a price-to-earnings-growth ratio of 3.56 and a beta of 1.30. Lantheus has a twelve month low of $12.80 and a twelve month high of $24.45.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Further Reading: Technical Analysis of Stocks, How Can It Help
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.